[{"id":"21st-century-cures-act","name":"21st Century Cures Act","tldr":"A 2016 US law that funded the Cancer Moonshot, created the RMAT designation for cell and gene therapies, told the FDA to work out how real-world data could support approvals, and made companies publish how patients can request unapproved drugs.","route":"/terms/21st-century-cures-act/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"abigail-alliance","name":"Abigail Alliance v. von Eschenbach (2007)","tldr":"A 2007 US appeals court ruling that terminally ill patients have no constitutional right to buy unapproved drugs after phase 1, which pushed the access movement toward legislation and eventually the Right to Try Act.","route":"/terms/abigail-alliance/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"amnog","name":"AMNOG (Germany, 2011)","tldr":"Germany's 2011 law under which a new medicine is sold at the company's price from day one but must show, within six months, how much better it is than the existing standard; the verdict then drives a negotiated price that applies nationwide.","route":"/terms/amnog/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"de","href":"/tagged/de/","tip":"Every record tagged de."}]},"sortKeys":{"year":0}},{"id":"law-scotland-assisted-dying-bill","name":"Assisted Dying for Terminally Ill Adults (Scotland) Bill","tldr":"This Scottish member's bill would have let eligible terminally ill adults in Scotland ask for help from health professionals to end their own life. It fell at the final stage on 17 March 2026, so it is not law.","route":"/terms/law-scotland-assisted-dying-bill/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"myriad-ruling","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","tldr":"The 2013 US Supreme Court ruling that human genes as they occur in nature cannot be patented, which ended one company's monopoly on BRCA testing and let hereditary cancer testing become cheap and widely available.","route":"/terms/myriad-ruling/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"bpcia","name":"Biologics Price Competition and Innovation Act 2010","tldr":"The 2010 US law that created a route for copies of biologic drugs such as trastuzumab and rituximab, while giving the original twelve years of protection from those copies.","route":"/terms/bpcia/","kind":"term","molecule":"trastuzumab","modality":"Monoclonal antibody (anti-HER2)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"law-california-end-of-life-option-act","name":"California End of Life Option Act (2015)","tldr":"California's End of Life Option Act allows an adult diagnosed with a terminal disease who meets the Act's conditions to request aid-in-dying drugs from their attending physician.","route":"/terms/law-california-end-of-life-option-act/","kind":"term","schematic":{"id":"hospice-end-of-life","sections":["supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"korea-cancer-control-act","name":"Cancer Control Act (Republic of Korea)","tldr":"South Korea's national cancer law, passed in 2003, obliges the government to run cancer screening, a cancer registry, home care and survivorship programmes, to help poorer patients with treatment costs, and it is the legal basis of the National Cancer Center.","route":"/terms/korea-cancer-control-act/","kind":"term","schematic":{"id":"cancer-registries-surveillance","sections":["prevention","ai-computation"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"kr","href":"/tagged/kr/","tip":"Every record tagged kr."}]},"sortKeys":{"year":0}},{"id":"cancer-drugs-fund","name":"Cancer Drugs Fund (England)","tldr":"An NHS England fund that pays for promising cancer drugs while more evidence is collected, born in 2010 as a political fix for drugs NICE had refused and rebuilt in 2016 into a time-limited managed access scheme with a fixed budget.","route":"/terms/cancer-drugs-fund/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"china-drug-administration-law","name":"China Drug Administration Law (2019) and expedited pathways","tldr":"China rewrote its drug law in 2019 and its registration rules in 2020, writing in priority review, conditional approval, breakthrough designation and acceptance of foreign trial data, which turned the world's slowest big regulator into one that approves cancer drugs within months of the FDA.","route":"/terms/china-drug-administration-law/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"cn","href":"/tagged/cn/","tip":"Every record tagged cn."}]},"sortKeys":{"year":0}},{"id":"china-hgr-rules","name":"China Human Genetic Resources rules (2019, 2023)","tldr":"Chinese rules that treat blood, tissue and genetic data from Chinese people as a national resource: foreign organisations cannot collect them, international collaborations need approval or filing, and exporting samples or sequence data needs a permit, which affects every global cancer trial with Chinese sites.","route":"/terms/china-hgr-rules/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"cn","href":"/tagged/cn/","tip":"Every record tagged cn."}]},"sortKeys":{"year":0}},{"id":"china-vbp-nrdl","name":"China National Reimbursement Drug List negotiation and volume-based procurement","tldr":"China's two price levers: an annual negotiation, since 2017, in which a new cancer drug wins national reimbursement only by cutting its price, often by half or more, and tenders since 2018 in which generic makers bid for guaranteed hospital volumes, collapsing prices of off-patent drugs.","route":"/terms/china-vbp-nrdl/","kind":"term","molecule":"imatinib","modality":"Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"cn","href":"/tagged/cn/","tip":"Every record tagged cn."}]},"sortKeys":{"year":0}},{"id":"eu-clinical-trials-regulation","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","tldr":"The EU rule, in force since January 2022, under which a cancer trial is submitted once through a single portal for all the countries it will run in, with results made public, replacing a 2001 directive that made every country's approval separate.","route":"/terms/eu-clinical-trials-regulation/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"declaration-of-helsinki","name":"Declaration of Helsinki","tldr":"The medical profession's own ethics code for research on people, adopted in 1964 and revised most recently in 2024, which every cancer trial protocol cites: informed consent, independent ethics review, the welfare of the participant above the interests of science, and limits on placebo controls.","route":"/terms/declaration-of-helsinki/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"intl","href":"/tagged/intl/","tip":"Every record tagged intl."}]},"sortKeys":{"year":0}},{"id":"eu-data-exclusivity","name":"EU data and market protection (8+2+1)","tldr":"In the EU a new medicine's trial data cannot be relied on by a generic or biosimilar for eight years, the copy cannot be sold for ten, and an eleventh year is added for a valuable new indication; it is the target of the 2023 reform.","route":"/terms/eu-data-exclusivity/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"eu-hta-regulation","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","tldr":"From January 2025 every new cancer medicine in the EU gets one shared assessment of how well it works compared with existing treatments, done jointly by member states, so that each country's payer no longer repeats the clinical review, though each still decides on price.","route":"/terms/eu-hta-regulation/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"eu-pharma-package","name":"EU pharmaceutical package reform (2023 proposal)","tldr":"The biggest rewrite of EU medicines law in twenty years, proposed in 2023: shorter default protection from generic competition with extensions for launching everywhere in the EU and for meeting unmet needs, faster assessments, and tighter orphan and paediatric rules, argued over by Parliament and Council since.","route":"/terms/eu-pharma-package/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"european-health-data-space","name":"European Health Data Space Regulation (EU) 2025/327","tldr":"A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.","route":"/terms/european-health-data-space/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"expanded-access","name":"Expanded access (compassionate use)","tldr":"The regulated way a seriously ill patient who cannot join a trial can get an unapproved drug: the doctor asks the company, the company agrees, and the regulator reviews the request, usually within days for a single patient.","route":"/terms/expanded-access/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"tobacco-control-act","name":"Family Smoking Prevention and Tobacco Control Act 2009","tldr":"The 2009 US law that finally gave the FDA power over tobacco products, the cause of roughly a third of cancer deaths, including authority to ban flavours, restrict marketing and set nicotine levels, though it may not ban cigarettes or nicotine outright.","route":"/terms/tobacco-control-act/","kind":"term","schematic":{"id":"smoking-cessation-after-diagnosis","sections":["nutrition-lifestyle","supportive-care","prevention"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."},{"label":"prevention","href":"/tagged/prevention/","tip":"Every record tagged prevention."}]},"sortKeys":{"year":0}},{"id":"fdasia-2012","name":"FDASIA 2012 and the origins of the expedited programmes","tldr":"The 2012 US law that created Breakthrough Therapy designation and made the paediatric study laws permanent, sitting on top of the 1992 user-fee law that gave the FDA review deadlines and the 1997 law that created Fast Track.","route":"/terms/fdasia-2012/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"fdora-2022","name":"FDORA 2022 accelerated approval reforms","tldr":"A December 2022 US law that lets the FDA insist the confirmatory trial for an accelerated approval is already running before the drug is approved, and gives it a quicker way to withdraw a drug when confirmation fails.","route":"/terms/fdora-2022/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"fdca","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","tldr":"The 1938 US law that makes a company prove a medicine is safe before selling it, and the 1962 amendments that added the requirement to prove it works, which is why every cancer drug approval rests on controlled trials.","route":"/terms/fdca/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"france-early-access","name":"France: early access (accès précoce), formerly ATU","tldr":"France pays for promising medicines before they are approved or reimbursed: the ATU system did this from 1994, and since July 2021 the Haute Autorité de Santé grants early access for presumed innovative drugs in serious diseases, with the company setting the price and repaying the difference later.","route":"/terms/france-early-access/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"fr","href":"/tagged/fr/","tip":"Every record tagged fr."}]},"sortKeys":{"year":0}},{"id":"gdpr","name":"GDPR and health data (Regulation (EU) 2016/679)","tldr":"The EU's 2016 data law, applied since May 2018, that treats health and genetic data as a special category needing a specific legal basis, gives people rights over their records, and shapes how cancer registries, biobanks and trials share data, including across borders.","route":"/terms/gdpr/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"gina","name":"GINA (Genetic Information Nondiscrimination Act 2008)","tldr":"A 2008 US law that stops health insurers and employers using your genetic test results against you, so a BRCA or Lynch syndrome result cannot raise your premiums or cost you a job; it does not cover life, disability or long-term care insurance.","route":"/terms/gina/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"hatch-waxman","name":"Hatch-Waxman Act 1984","tldr":"The 1984 US law that created the modern generic drug: copies are approved on bioequivalence alone, brands get patent time restored for years lost in review, and the two sides fight it out through patent challenges with a 30-month pause.","route":"/terms/hatch-waxman/","kind":"term","molecule":"imatinib","modality":"Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"hipaa","name":"HIPAA (Health Insurance Portability and Accountability Act)","tldr":"The 1996 US law whose privacy rules govern how hospitals, insurers and their contractors may use and share a patient's health records, including tumour genomics, and what must be stripped out before data can be used for research without consent.","route":"/terms/hipaa/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"ich-gcp","name":"ICH good clinical practice (E6)","tldr":"The international standard for how a clinical trial must be designed, run, recorded and reported so that regulators in the United States, Europe, Japan and now China will accept its data; the third version was adopted in 2025 to fit trials that use electronic records and run across many countries.","route":"/terms/ich-gcp/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"intl","href":"/tagged/intl/","tip":"Every record tagged intl."}]},"sortKeys":{"year":0}},{"id":"ilap","name":"ILAP (Innovative Licensing and Access Pathway)","tldr":"The UK's post-Brexit scheme, launched in 2021 and refreshed in 2025, that brings the medicines regulator, NICE and the NHS together early in a drug's development so that licensing and the decision to pay for it can happen close together.","route":"/terms/ilap/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"india-new-drugs-rules-2019","name":"India New Drugs and Clinical Trials Rules 2019","tldr":"India's 2019 rules for approving new drugs and running trials set deadlines for the regulator, fixed compensation for trial injuries, and allowed waivers of local trials for drugs already approved abroad, a waiver widened in 2024 for cancer and orphan drugs.","route":"/terms/india-new-drugs-rules-2019/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"in","href":"/tagged/in/","tip":"Every record tagged in."}]},"sortKeys":{"year":0}},{"id":"inflation-reduction-act","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","tldr":"The 2022 US law that for the first time lets Medicare negotiate prices for top-selling drugs, capped what older patients pay for prescriptions at 2,000 dollars a year, and exempted drugs approved only for rare diseases, an exemption widened in 2025.","route":"/terms/inflation-reduction-act/","kind":"term","molecule":"ibrutinib","modality":"Small-molecule covalent BTK inhibitor (first generation)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"innovative-medicines-fund","name":"Innovative Medicines Fund (England)","tldr":"A fund launched in 2022 that does for non-cancer medicines what the Cancer Drugs Fund does for cancer: pays for a promising but uncertain drug for a limited period while evidence is gathered, with the same budget of 340 million pounds.","route":"/terms/innovative-medicines-fund/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"ireland-alcohol-act-cancer-warning","name":"Ireland: Public Health (Alcohol) Act 2018, section 12, and the cancer warning on alcohol","tldr":"Ireland's 2018 alcohol law requires alcohol containers, pubs and online sellers to carry a warning about the direct link between alcohol and fatal cancers. The labelling rules made under it set the wording \"There is a direct link between alcohol and fatal cancers\".","route":"/terms/ireland-alcohol-act-cancer-warning/","kind":"term","schematic":{"id":"alcohol-reduction-labelling","sections":["nutrition-lifestyle","prevention"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"ie","href":"/tagged/ie/","tip":"Every record tagged ie."}]},"sortKeys":{"year":0}},{"id":"italy-law-193-2023-oncological-oblivion","name":"Italy: Law 193 of 7 December 2023 on the right to be forgotten after cancer","tldr":"Since 2 January 2024 Italian law forbids banks, insurers and other businesses from asking about a cancer whose active treatment ended more than ten years earlier without relapse, or five years if the cancer began before age 21.","route":"/terms/italy-law-193-2023-oncological-oblivion/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"it","href":"/tagged/it/","tip":"Every record tagged it."}]},"sortKeys":{"year":0}},{"id":"japan-conditional-early-approval","name":"Japan conditional early approval and time-limited approval","tldr":"Japan can approve a medicine for a serious disease on early data when a confirmatory trial would be hard to run, on condition that evidence is gathered after launch; for cell and tissue products a 2014 law allows a time-limited approval that must be confirmed within seven years.","route":"/terms/japan-conditional-early-approval/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"jp","href":"/tagged/jp/","tip":"Every record tagged jp."}]},"sortKeys":{"year":0}},{"id":"japan-cancer-registry-promotion-act","name":"Japan: Act on the Promotion of Cancer Registries (Act No. 111 of 2013)","tldr":"A 2013 Japanese law created a single national cancer registry: every hospital, and clinics designated by the prefecture, must report each newly diagnosed cancer, with its stage and treatment, to the prefectural governor.","route":"/terms/japan-cancer-registry-promotion-act/","kind":"term","schematic":{"id":"cancer-registries-surveillance","sections":["prevention","ai-computation"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"jp","href":"/tagged/jp/","tip":"Every record tagged jp."}]},"sortKeys":{"year":0}},{"id":"mqsa-breast-density-notice","name":"Mammography Quality Standards Act (MQSA) and the breast density notice","tldr":"A US federal law sets quality standards for mammography facilities. Its rules require each woman's results letter to say in plain words whether her breast tissue is dense, because dense tissue makes cancer harder to see on a mammogram and raises the risk of breast cancer.","route":"/terms/mqsa-breast-density-notice/","kind":"term","schematic":{"id":"mammography","sections":["imaging","early-detection"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"law-canada-maid","name":"Medical assistance in dying in Canada (Criminal Code, section 241.2)","tldr":"In Canada, an adult who can make health decisions, has a serious and incurable condition with intolerable suffering, and asks voluntarily may receive medical assistance in dying after being told about all ways to relieve suffering, including palliative care.","route":"/terms/law-canada-maid/","kind":"term","schematic":{"id":"palliative-care","sections":["supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"medicare-ced","name":"Medicare coverage with evidence development","tldr":"Medicare's way of paying for a promising but uncertain test or treatment only for patients enrolled in a registry or study, used for PET scans in cancer from 2006 and now the frame for how Medicare covers gene panels and cell therapies.","route":"/terms/medicare-ced/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"medicare-negotiation-2028-cancer-drugs","name":"Medicare drug price negotiation for 2028: apalutamide, ribociclib, abemaciclib and lenvatinib","tldr":"Four cancer medicines are among the drugs selected for the third round of Medicare price negotiation, with prices due from 1 January 2028: Erleada (apalutamide), Kisqali (ribociclib), Verzenio (abemaciclib) and Lenvima (lenvatinib). The negotiated prices had not been published in CMS's data file by November 2026.","route":"/terms/medicare-negotiation-2028-cancer-drugs/","kind":"term","molecule":"apalutamide","modality":"Small-molecule AR antagonist","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"medicare-negotiation-2026-cancer-drug","name":"Medicare negotiated price for ibrutinib (Imbruvica), first cycle","tldr":"The first ten drugs with a Medicare-negotiated price, in effect from 1 January 2026, included one cancer medicine, ibrutinib (Imbruvica). Its price is set per 30-day supply and rose with inflation from 2027.","route":"/terms/medicare-negotiation-2026-cancer-drug/","kind":"term","molecule":"ibrutinib","modality":"Small-molecule covalent BTK inhibitor (first generation)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"medicare-negotiation-2027-cancer-drugs","name":"Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib","tldr":"Of the fifteen drugs whose Medicare-negotiated prices start on 1 January 2027, four are cancer medicines: Xtandi (enzalutamide), Pomalyst (pomalidomide), Ibrance (palbociclib) and Calquence (acalabrutinib).","route":"/terms/medicare-negotiation-2027-cancer-drugs/","kind":"term","molecule":"enzalutamide","modality":"Small-molecule AR antagonist","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"medicines-medical-devices-act-2021","name":"Medicines and Medical Devices Act 2021","tldr":"The 2021 UK law, passed after Brexit, that gives ministers power to rewrite the rules for licensing medicines, running trials and regulating devices without new primary legislation, and that created a patient safety commissioner.","route":"/terms/medicines-medical-devices-act-2021/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"law-netherlands-euthanasia-act","name":"Netherlands Termination of Life on Request and Assisted Suicide (Review Procedures) Act (2001)","tldr":"In the Netherlands, a doctor may end a patient's life on request, or assist suicide, only when the patient asks voluntarily, the suffering is unbearable with no prospect of improvement and the doctor meets six legal due care criteria. Patients have no right to it and doctors may refuse.","route":"/terms/law-netherlands-euthanasia-act/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"netherlands-ex-cancer-patients-insurance-decree","name":"Netherlands: the 2020 decree on insurance examinations of former cancer patients","tldr":"Since 1 January 2021 Dutch insurers may not ask whether someone has had cancer when they apply for term life or funeral insurance, once ten years have passed in full remission with no recurrence, or five years if the cancer was diagnosed before age 21.","route":"/terms/netherlands-ex-cancer-patients-insurance-decree/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"nl","href":"/tagged/nl/","tip":"Every record tagged nl."}]},"sortKeys":{"year":0}},{"id":"nexavar-compulsory-licence","name":"Nexavar compulsory licence (India, 2012)","tldr":"In March 2012 India's patent office let Natco make a generic of Bayer's kidney and liver cancer drug sorafenib at about 3 percent of the branded price, paying a royalty, because Bayer had priced it beyond most Indians' reach; it remains the leading example of a compulsory licence on a cancer drug.","route":"/terms/nexavar-compulsory-licence/","kind":"term","molecule":"sorafenib","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"in","href":"/tagged/in/","tip":"Every record tagged in."}]},"sortKeys":{"year":0}},{"id":"nice-methods","name":"NICE technology appraisal methods (2022)","tldr":"The rulebook NICE uses to decide whether the NHS in England should pay for a medicine: a cost per quality-adjusted life year usually between 20,000 and 30,000 pounds, with extra weight since 2022 for severe diseases in place of the old bonus for end-of-life cancer drugs.","route":"/terms/nice-methods/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"novartis-glivec-ruling","name":"Novartis v. Union of India (Glivec, 2013)","tldr":"In April 2013 India's Supreme Court refused Novartis a patent on the crystal form of imatinib used in Glivec, ruling that a new form of a known drug must show improved therapeutic effect, a decision that kept Indian generics of the leukaemia drug legal and became the model for anti-evergreening laws elsewhere.","route":"/terms/novartis-glivec-ruling/","kind":"term","molecule":"imatinib","modality":"Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)","facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"in","href":"/tagged/in/","tip":"Every record tagged in."}]},"sortKeys":{"year":0}},{"id":"law-oregon-death-with-dignity-act","name":"Oregon Death with Dignity Act (1997)","tldr":"Oregon's 1997 law allows a capable adult with a terminal disease expected to cause death within six months to request medication they take themselves to end their life, after a voluntary written request confirmed by two physicians.","route":"/terms/law-oregon-death-with-dignity-act/","kind":"term","schematic":{"id":"hospice-end-of-life","sections":["supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"orphan-drug-act","name":"Orphan Drug Act 1983","tldr":"The 1983 US law that pays companies to develop drugs for rare diseases with seven years of market exclusivity, tax credits and fee waivers, which is why so many cancer drugs are first approved for a rare subtype.","route":"/terms/orphan-drug-act/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"pact-act-2022-cancer-presumptions","name":"PACT Act 2022: cancers presumed service-connected for US veterans exposed to burn pits and other toxins","tldr":"A 2022 US law means a veteran who served where burn pits and other toxins were used, and later develops one of a listed set of cancers, does not have to prove the service caused it to receive veterans' benefits. The list covers head, neck, respiratory, digestive, reproductive, kidney and brain cancers, lymphomas, melanoma, pancreatic cancer and glioblastoma.","route":"/terms/pact-act-2022-cancer-presumptions/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":["Head and neck squamous cell carcinoma","Glioma & glioblastoma","Melanoma","Pancreatic ductal adenocarcinoma","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma is the hardest to treat: surgery, radiotherapy with temozolomide and tumour treating fields are its backbone, with CAR-T into the brain and focused ultrasound in trials."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"bpca-prea","name":"Paediatric drug laws: BPCA and PREA","tldr":"Two US laws, one a carrot and one a stick, that get new drugs studied in children: BPCA gives six extra months of exclusivity for doing requested paediatric studies, and PREA requires paediatric assessments, though until 2020 cancer drugs mostly escaped it.","route":"/terms/bpca-prea/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"pipl","name":"PIPL (China Personal Information Protection Law 2021)","tldr":"China's 2021 privacy law, in force since November 2021, treats medical and health data as sensitive information requiring separate consent, and together with the Data Security Law restricts sending patient data out of China, which shapes every international cancer trial run there.","route":"/terms/pipl/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"cn","href":"/tagged/cn/","tip":"Every record tagged cn."}]},"sortKeys":{"year":0}},{"id":"portugal-law-75-2021-right-to-be-forgotten","name":"Portugal: Law 75/2021 and the right to be forgotten in credit and insurance","tldr":"Since 1 January 2022 Portuguese law stops banks and insurers from collecting health information about a serious illness, cancer included, once ten years have passed since the end of treatment, or five years if the illness occurred before age 21, when someone applies for a mortgage, consumer credit or the insurance tied to it.","route":"/terms/portugal-law-75-2021-right-to-be-forgotten/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"pt","href":"/tagged/pt/","tip":"Every record tagged pt."}]},"sortKeys":{"year":0}},{"id":"eu-orphan-regulation","name":"Regulation (EC) No 141/2000: EU orphan medicines","tldr":"The EU's 2000 answer to the US Orphan Drug Act: ten years during which no similar medicine may be authorised for the same rare disease, plus fee reductions and scientific advice, for conditions affecting no more than 5 in 10,000 people.","route":"/terms/eu-orphan-regulation/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"eu-paediatric-regulation","name":"Regulation (EC) No 1901/2006: EU paediatric medicines","tldr":"Since 2007 every new medicine in the EU must come with an agreed plan for studying it in children, or a waiver, and completing the plan earns six extra months of patent protection; a loophole let adult-cancer drugs skip children, which is now being closed.","route":"/terms/eu-paediatric-regulation/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"eu-regulation-726-2004","name":"Regulation (EC) No 726/2004: the EU centralised procedure","tldr":"The 2004 EU regulation under which every new cancer medicine is assessed once by the European Medicines Agency and authorised for all member states by the European Commission, and which also carries the rules for conditional authorisation and compassionate use.","route":"/terms/eu-regulation-726-2004/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"right-to-try","name":"Right to Try Act 2018 and state right-to-try laws","tldr":"A 2018 US law letting patients with life-threatening illnesses ask a company directly for a drug that has passed phase 1 without going through the FDA; companies still decide, and in practice most access happens through the older expanded access route.","route":"/terms/right-to-try/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"right-to-be-forgotten-cancer-europe","name":"Right-to-be-forgotten laws for cancer survivors in Europe","tldr":"Ten European countries have rules that let a person who has had cancer stop declaring it when applying for insurance or a loan once a set time has passed without the cancer coming back: five years in some countries, ten in others, and five everywhere for a cancer diagnosed in childhood.","route":"/terms/right-to-be-forgotten-cancer-europe/","kind":"term","schematic":{"id":"rejuv-life-insurance-loans-and-the-right-to-be-forgotten","sections":["rejuvenation","supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"sakigake","name":"Sakigake designation (Japan)","tldr":"Japan's fast lane for innovative medicines developed there first: a designated drug gets priority consultation, a six-month review instead of twelve, and a price premium, in return for early development in Japan.","route":"/terms/sakigake/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"jp","href":"/tagged/jp/","tip":"Every record tagged jp."}]},"sortKeys":{"year":0}},{"id":"law-spain-euthanasia-act","name":"Spain Organic Law 3/2021 regulating euthanasia","tldr":"Spain's 2021 law gives adults with a serious and incurable illness, or a serious, chronic and disabling condition, the right to request help to die, after two written requests at least 15 days apart and information about palliative care.","route":"/terms/law-spain-euthanasia-act/","kind":"term","schematic":{"id":"palliative-care","sections":["supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"spain-rdl-5-2023-oncological-oblivion","name":"Spain: Royal Decree-Law 5/2023 and the right to be forgotten after cancer","tldr":"Since 2023 Spanish law says that five years after cancer treatment ends with no relapse, a person does not have to declare the cancer when taking out life insurance, and an insurer or other business may not refuse them or charge them more because of it.","route":"/terms/spain-rdl-5-2023-oncological-oblivion/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"es","href":"/tagged/es/","tip":"Every record tagged es."}]},"sortKeys":{"year":0}},{"id":"state-biomarker-testing-laws","name":"State biomarker testing coverage laws","tldr":"A wave of US state laws, starting in 2021, that require insurers regulated by the state and often Medicaid to pay for the tumour and inherited gene tests that decide which targeted drug a patient should get.","route":"/terms/state-biomarker-testing-laws/","kind":"term","schematic":{"id":"companion-diagnostic","sections":["diagnostics"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"spc","name":"Supplementary protection certificate (EU)","tldr":"The EU's version of patent term restoration: up to five extra years of protection for a medicine to make up for the years spent in trials and review, so that a cancer drug gets about fifteen years of protected sales after approval, plus six months for paediatric studies.","route":"/terms/spc/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"eu","href":"/tagged/eu/","tip":"Every record tagged eu."}]},"sortKeys":{"year":0}},{"id":"law-england-wales-terminally-ill-adults-bill","name":"Terminally Ill Adults (End of Life) Bill (England and Wales)","tldr":"This private member's bill would have let terminally ill adults in England and Wales ask for help to end their own life. It passed the House of Commons in June 2025 but did not complete its House of Lords stages in that session, so it is not law.","route":"/terms/law-england-wales-terminally-ill-adults-bill/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"common-rule","name":"The Common Rule (45 CFR 46)","tldr":"The US rules that require an ethics committee to approve research on people and require informed consent, written in 1991 and rewritten in 2018 so that a single committee can oversee a multi-site cancer trial and patients can give broad consent for future use of their samples.","route":"/terms/common-rule/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"tobacco-21","name":"Tobacco 21","tldr":"Since December 2019 it has been illegal across the United States to sell tobacco or vaping products to anyone under 21, a rule that started in one Massachusetts town and spread state by state, aimed at the years when most smokers start.","route":"/terms/tobacco-21/","kind":"term","schematic":{"id":"smoking-cessation-after-diagnosis","sections":["nutrition-lifestyle","supportive-care","prevention"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."},{"label":"prevention","href":"/tagged/prevention/","tip":"Every record tagged prevention."}]},"sortKeys":{"year":0}},{"id":"trips-doha","name":"TRIPS Agreement and the Doha Declaration","tldr":"The 1994 world trade treaty that obliged every member country to grant twenty-year patents on medicines, and the 2001 declaration confirming that countries may still issue compulsory licences and protect public health; together they set the global terms on which cancer drugs are priced and copied.","route":"/terms/trips-doha/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"intl","href":"/tagged/intl/","tip":"Every record tagged intl."}]},"sortKeys":{"year":0}},{"id":"uk-data-protection-act","name":"UK Data Protection Act 2018 and health data law","tldr":"The UK's data law, which keeps the EU's GDPR in domestic form and adds NHS-specific rules, so that cancer registries and research can use patient records under a public-interest basis, patients can opt out of secondary uses, and a 2025 Act loosened the consent rules for scientific research.","route":"/terms/uk-data-protection-act/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"uk","href":"/tagged/uk/","tip":"Every record tagged uk."}]},"sortKeys":{"year":0}},{"id":"us-regulatory-exclusivity","name":"US regulatory exclusivity periods","tldr":"Separate from patents, US law gives an approved drug fixed periods during which the FDA will not approve a copy: five years for a new chemical, three for new clinical studies, seven for an orphan indication, twelve for a biologic, plus six months for paediatric studies.","route":"/terms/us-regulatory-exclusivity/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"us-state-fertility-preservation-laws","name":"US state fertility preservation coverage laws","tldr":"Some US states have laws that require certain health insurers to pay for fertility preservation, such as egg or sperm freezing, for people whose cancer treatment may cause infertility. Check your state on the Alliance for Fertility Preservation map before treatment starts.","route":"/terms/us-state-fertility-preservation-laws/","kind":"term","schematic":{"id":"fertility-preservation","sections":["supportive-care","rejuvenation"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"law-victoria-voluntary-assisted-dying-act","name":"Victoria Voluntary Assisted Dying Act 2017 (Australia)","tldr":"In the Australian state of Victoria, people at the end of life who meet the law's eligibility criteria can ask for voluntary assisted dying. Amendments passed in November 2025 take effect from April 2027.","route":"/terms/law-victoria-voluntary-assisted-dying-act/","kind":"term","schematic":{"id":"palliative-care","sections":["supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"law-washington-death-with-dignity-act","name":"Washington Death with Dignity Act (Initiative 1000, 2008)","tldr":"Washington's law, passed by public vote in 2008, allows some terminally ill adult residents expected to die within six months to request medication to end their life as part of end-of-life care.","route":"/terms/law-washington-death-with-dignity-act/","kind":"term","schematic":{"id":"hospice-end-of-life","sections":["supportive-care"]},"facets":{"kind":["Term"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}},{"id":"wtc-health-program-covered-cancers","name":"World Trade Center Health Program and the cancers it covers (Zadroga Act)","tldr":"Responders and survivors of the 11 September 2001 attacks in New York who later develop one of a long list of cancers can have their care paid for by a US federal programme. The list covers most solid cancers and all blood cancers, plus any cancer in someone under 20 and any rare cancer.","route":"/terms/wtc-health-program-covered-cancers/","kind":"term","term":{"category":"Regulation & policy"},"facets":{"kind":["Term"],"cancers":["Mesothelioma","Thyroid cancer","Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Term","tip":"Glossary with plain-English TL;DRs and Wikipedia links."},"cancers":[{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."},{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[{"label":"us","href":"/tagged/us/","tip":"Every record tagged us."}]},"sortKeys":{"year":0}}]